Articles

Pfizer's Latest Developments: Insights for Investors and Executives

This article analyzes Pfizer's recent developments, focusing on their implications for business development teams and investors. Discover key insights and strategic impacts.

Sen. Bill Cassidy Loses Primary: Implications for Pharma

Sen. Bill Cassidy's primary loss signals a shift in political dynamics that could impact pharmaceutical investments and strategies. This article explores the implications for the industry.

U.K. Advocacy Groups Challenge U.S. Pharma Trade Deal

U.K. advocacy groups are threatening court action over a crucial provision in the U.S. pharma trade deal. This could have significant implications for the pharmaceutical industry.

Hantavirus Outbreak: Lessons from COVID-19 for Pharma

The hantavirus outbreak is raising concerns reminiscent of COVID-19, including conspiracy theories. This article explores its implications for the pharmaceutical industry.

FDA Shake-Up: Implications for Oncology and Beyond

The recent departure of an FDA official raises questions about the future of drug approvals and scrutiny in oncology and beyond. This analysis explores the implications for pharmaceutical teams.

Ebola Exposure Risk: Implications for Pharma Stakeholders

Recent Ebola outbreak in Congo raises concerns for American nationals. This article explores the implications for pharmaceutical stakeholders.

Leadership Changes at CDER and CBER: Implications for Oncology

Recent leadership changes at CDER and CBER following Makary's exit raise questions about the future of oncology drug approvals. This analysis explores the implications for investors and pharma teams.

Biologics and Manufacturing Challenges in Biopharma

As biologics take the lead in biopharma pipelines, manufacturing challenges are hindering new product launches. This article explores the implications for the industry.

Unlocking Value from Mature Drug Products: Strategic Outsourcing

This article discusses the potential of strategic outsourcing to maximize the value of mature drug products, providing insights for B2B readers in the pharmaceutical sector.

The Misconception of Patient Autonomy in Childhood Vaccine Policies

This article examines the misconception that patient autonomy is central to childhood vaccine policies, providing insights for pharmaceutical professionals.

Restoring Credibility to the CDC’s Vaccine Advisory Committee

This article discusses the need for restoring credibility to the CDC’s vaccine advisory committee and its implications for the pharmaceutical industry.

Why Pharma Brands Should Embrace Consumer Branding Strategies

Pharma brands are increasingly required to adopt consumer branding strategies to remain competitive. This article explores the implications and strategies for success.

The China Question: A Divide in Biotech

The biotech industry faces a critical juncture as the China question creates a divide. This article explores the implications for pharma teams and investors.

AI-Driven Transformation in Pharma Marketing

This article delves into the transformative role of AI in creating patient-centric marketing strategies in the pharmaceutical industry.

Regeneron Immunotherapy Combo Fails in Melanoma Trial

Regeneron's recent melanoma trial results raise questions about the future of its immunotherapy combo. Analysts must assess the competitive landscape and investment implications.

How Compliance and Data are Transforming Pharma TV Marketing

This article examines the evolving landscape of pharma TV marketing, driven by compliance and data analytics. Discover the implications for industry stakeholders.

How AI Search is Transforming Pharma Marketing

AI search is reshaping the landscape of pharma marketing. This article explores its implications for business development and competitive positioning.

Insights from Executive Interviews at Fierce Pharma Engage 2026

This article delves into the executive interviews at Fierce Pharma Engage 2026, highlighting key insights and their implications for the pharmaceutical sector.

Precision Engagement in Pharma: Insights from PharmaForceIQ

Explore how PharmaForceIQ is transforming precision engagement in pharma, driving strategic insights and competitive advantages.

FDA Approves AstraZeneca's Innovative Hypertension Drug

AstraZeneca's innovative hypertension drug has received FDA approval, marking a significant milestone in hypertension treatment. This article explores the implications for the pharmaceutical industry.